Clostridioides (Clostridium) difficile is an opportunistic pathogen known for its ability to 12 colonize the human gut under conditions of dysbiosis. Several aspects of its carbon and amino 13 acid metabolism have been investigated, but its cobamide (vitamin B 12 and related cofactors) 14 metabolism remains largely unexplored. C. difficile has seven predicted cobamide-dependent 15 metabolisms encoded in its genome in addition to a nearly complete cobamide biosynthesis 16 pathway and a cobamide uptake system. To address the importance of cobamides to C. difficile, 17
intermediate cobinamide, and produces other cobamides if provided an alternative lower ligand. 23
The ability of C. difficile 630 ∆erm to take up cobamides and Cbi at micromolar or lower 24 concentrations requires the transporter BtuFCD. Genomic analysis revealed genetic variations in 25 in the btuFCD locus of different C. difficile strains, which may result in differences in the ability 26 to take up cobamides and Cbi. These results together demonstrate that, like other aspects of its 27 physiology, cobamide metabolism in C. difficile is versatile. 28 29 Importance 30
The ability of the opportunistic pathogen Clostridioides difficile to cause disease is closely linked 31 to its propensity to adapt to conditions created by dysbiosis of the human gut microbiota. The 32 cobamide (vitamin B 12 ) metabolism of C. difficile has been underexplored, though it has seven 33
Introduction 40
The human gut microbiota is a complex community composed of hundreds to thousands 41 of species of bacteria, archaea, and eukaryotic microbes (1). Members of this community 42 compete for nutrients such as carbon sources, but also release metabolites that benefit other 43 members. The exchange of B vitamins, particularly vitamin B 12 , is thought to be prevalent in 44 many environments because most bacteria lack the ability to synthesize some of the cofactors 45 they require for enzyme catalysis (2-6), and instead must acquire them from other organisms (7) . 46
Such nutrient cross-feeding interactions can influence bacterial metabolism in ways that can 47 affect not only the microbiota, but also host health (8, 9) . 48 Clostridioides (Clostridium) difficile is a human intestinal pathogen that is among the 49 most common causes of nosocomial infections, with nearly 300,000 healthcare-associated cases 50 per year in the United States (10). C. difficile colonization of the gut is correlated with dysbiosis 51 of the gut microbiota (11). Its abilities to germinate from spores, proliferate in the gut, and cause 52 disease are impacted both positively and negatively by ecological and metabolic factors (12) (13) (14) . 53
The global alteration of the gut metabolome following antibiotic treatment is correlated with 54 increased susceptibility to C. difficile infection, and recent work has linked changes in the 55 relative abundance of specific metabolites to changes in the microbiome using model systems 56 (11, (15) (16) (17) . For example, succinate availability increases after disturbance of the microbiota, 57 allowing C. difficile expansion in a mouse model (18) . Additionally, specific commensal bacteria 58 have been shown to produce compounds that stimulate C. difficile metabolism. In a bi-59 association, Bacteroides thetaiotaomicron can break down host mucin and produce sialic acid, 60 which can be used by C. difficile for expansion in the gut (19). C. difficile can also induce other 61 members of the microbiota to produce indole, which is thought to create a more favorable 62 environment for the pathogen by inhibiting competing microbes (20) . 63 Some interactions with microbiota members have also been shown to be inhibitory to C. 64 difficile. Co-culturing with certain Bifidobacterium spp. on particular carbon sources reduces C. 65 difficile toxin production relative to monoculture (21). While primary bile acids produced by the 66 host promote C. difficile spore germination, Clostridium scindens and other 7α-dehydroxylating 67
Clostridia transform these compounds into secondary bile acids, which are inhibitory to C. 68 difficile (22, 23). The latter example illustrates that compounds in the same class can have 69 different effects on the disease state. Given the complexity of metabolic interactions in the 70 mammalian gut, many additional microbial metabolites likely influence the ability of C. difficile 71 to colonize and persist in the gut. 72
One class of metabolites that has not been explored for its ability to affect C. difficile 73 growth and virulence is cobamides, the vitamin B 12 (also called cobalamin) family of cofactors. 74
Cobamides are used in diverse microbial metabolisms including methionine synthesis, 75 deoxyribonucleotide synthesis, acetogenesis, and some carbon catabolism pathways. These 76 reactions are facilitated by fission of the Co-C bond to the cobamide upper ligand, which can be 77 a 5'-deoxyadenosyl group for radical reactions, a methyl group for methyltransferase reactions, 78 or a cyano group in the inactive vitamin form (24) (labeled as "R" in Fig. 1A ). Over 80% of all 79 sequenced bacteria (25-27) and 80% of sequenced human gut bacteria (2, 28, 29) have one or 80 more cobamide-dependent enzymes, suggesting that cobamides are widely used cofactors across 81 microbial ecosystems. Strikingly, fewer than 40% of bacterial species are predicted to produce 82 cobamides de novo (2, 25-28), and therefore over half of bacteria that use cobamides must 83 acquire them from their environment. Cobamides vary in the structure of the lower ligand ( Fig.  84 1A, B), and organisms studied to date are selective in which cobamides they can use (28, (30) (31) (32) (33) (34) (35) (36) (37) . 85
Seven cobamides in addition to the cobamide precursor cobinamide (Cbi, Fig. 1C ) have been 86 detected in the human gut (38). In an environment with plentiful, diverse cobamides and 87 cobamide precursors, a microbial species that requires a particular cobamide can either import 88 that cobamide, synthesize it de novo, chemically remodel available cobamides to the preferred 89 structure, or alter its need for the cobamide by using alternative pathways (8, 39) . 90
The seven predicted cobamide-dependent enzymes encoded in the C. difficile genome are 91 involved in methionine synthesis, nucleotide metabolism, and carbon metabolism ( experimental study suggests that it may be used for autotrophic growth by some C. difficile 101 strains (44). 102
The observation that C. difficile can grow without added cobamides in vitro (40) suggests 103 that it may not require cobamides under those conditions, or that it can biosynthesize cobamides. 104
However, all sequenced strains of C. difficile are missing hemA and hemL, the first two enzymes 105 in the cobamide biosynthesis pathway required for production of the precursor 5-aminolevulinic 106 acid (ALA) (45) (Fig. 1C) . Therefore, C. difficile is predicted to be able to produce a cobamide 107 only when ALA is available, as has been observed in three other bacteria (25) (Fig. 2) . In order 108 to use cobamide-dependent metabolisms, we predict that C. difficile requires cobamides or 109 precursors such as ALA from the gut. While ALA is an intermediate made in all tetrapyrrole-110 producing organisms, including the host, cobamides are only produced by some bacteria and 111 archaea (46). 112
To address the importance of cobamides for C. difficile metabolism and to understand 113 how C. difficile acquires cobamides, we examined C. difficile 630 ∆erm and mutant derivatives 114 in vitro under cobamide-dependent conditions. We found that the bacterium can use a 115 surprisingly diverse array of cobamides for methionine and deoxyribonucleotide synthesis, and 116 can use alternative nutrient sources or enzymes to fulfill its metabolic needs. In addition to 117 importing and using a variety of cobamides, when provided with ALA or the late intermediate 118 
C. difficile requires methionine or a cobamide for growth 125
To investigate cobamide-dependent metabolism in the model C. difficile strain 630 ∆erm, 126 we sought to culture the organism in conditions that require specific cobamide-dependent 127 enzymes. The C. difficile genome encodes the cobalamin-dependent methionine synthase MetH, 128 but does not contain the cobalamin-independent alternative enzyme MetE. The absence of a 129 complete cobamide biosynthesis pathway suggests that C. difficile requires either methionine or 130 a cobamide in its growth medium. Previously, methionine was classified as a "growth-131 enhancing," but not essential, amino acid in a medium containing cyanocobalamin (vitamin B 12 ) 132
for seven of eight strains tested (40, 47). To test whether C. difficile can use cobamides for 133 methionine synthesis and to identify the specific cobamides that support its MetH-dependent 134 growth, we cultured C. difficile in a defined medium lacking methionine with a range of 135 concentrations of cyanocobalamin, Cbi, and eight other cyanylated cobamides that we purified. 136 C. difficile was unable to grow in this medium without cobamide or methionine addition ( Fig.  137 3A), suggesting that, as predicted, it cannot produce cobamides de novo to support the activity of 138
MetH. Remarkably, unlike other bacteria that have been reported to use a limited number of 139 cobamides for methionine synthase activity (28, 48, 49), all of the cobamides and Cbi were able 140 to confer high growth yields to C. difficile at concentrations as low as 1 nM (Fig. 3A) . 141
Methionine addition also supported growth, though higher concentrations were required than for 142 cobamides (Fig. 3B ). We also observed robust growth with addition of ALA ( Fig. 3C) . CDIF630erm_RS16325, and nrdF, CDIF630erm_RS16320) and an oxygen-sensitive (class III) 150 RNR (nrdD, CDIF630erm_RS00990 and nrdG, CDIF630erm_RS00995). In principle, any of 151 these three isozymes could be used for deoxyribonucleotide synthesis from ribonucleotides, 152 although under anaerobic conditions only the class II and class III RNRs are expected to 153 function. Cobamide addition is not required for anaerobic growth of the parent strain C. difficile 154 630 ∆erm ∆pyrE in a casamino acid medium (CDDM) with glucose, and adding cobamides or 155 cobamide precursors did not affect growth yield (Supplemental Fig. 1 ), suggesting that the class 156 III RNR, NrdDG, is functional under these conditions. To test whether the class II RNR, NrdJ, is 157 functional, we deleted the nrdD and nrdG genes while providing exogenous cobalamin, using the 158 allelic exchange system in a ∆pyrE background (50). This strain could grow only with cobalamin 159
addition, suggesting that NrdJ is functional and NrdEF is not under these growth conditions (Fig.  160 4A). To determine which cobamides it requires, the ∆nrdDG strain was grown with the same 161 cobamides and precursors as in Fig. 3 . In contrast to MetH, NrdJ is more selective in the 162 cobamides it can use ( Fig. 4A ), as expected based on studies with other class II RNRs (33, 36, 163 51, 52). There was little growth with [Cre]Cba, [Phe]Cba, and [5-OHBza]Cba (Fig. 4A) . 164
Addition of ALA also supported NrdJ-dependent growth (Fig. 4B) . 165 166 C. difficile produces pseudocobalamin from the precursor ALA via the cbi genes 167
The observation that C. difficile could grow under cobamide-dependent conditions with 168 ALA or Cbi (Fig. 3A, C, Fig. 4 ) suggests that it can produce a cobamide from these precursors 169 using the cobamide biosynthetic genes encoded in its genome (25). To test this prediction, the 170 corrinoid fraction, which includes cobamides and late cobamide precursors including Cbi, was 171 extracted from the cell pellets of C. difficile 630 ∆erm grown with either ALA or Cbi. Consistent 172 with our predictions, HPLC analysis of the extracted corrinoids showed that C. difficile produced 173 a cobamide only when ALA or Cbi was added ( Fig. 5A ). Additionally, as predicted, corrinoid 174 analysis of a strain lacking the corrin ring biosynthesis genes cbiKLJHGFTEDC demonstrated 175 that these genes are necessary for cobamide synthesis from ALA, but not Cbi (Fig. 5A) . Because 176 C. difficile lacks all known genes for biosynthesis of benzimidazoles and attachment of phenolic 177 lower ligands, it is predicted to be incapable of producing benzimidazolyl or phenolyl 178 cobamides, but may produce a purinyl cobamide (49, 53-59). Indeed, the major cobamide 179 present in C. difficile corrinoid extracts co-eluted with the purinyl cobamide pseudocobalamin 180 ( Fig. 5A) . The UV-Vis spectrum of the major cobamide was consistent with a pseudocobalamin 181 standard (Supplemental Fig. 2C ). Mass spectrometry analysis verified that the major cobamide 182 extracted from cultures grown with ALA is pseudocobalamin (Supplemental Fig. 2A, B) . the cells (Fig. 6A) . 199
200

C. difficile requires btuFCD for efficient uptake of cobamides and Cbi 201
The presence of cobamides in the cellular fraction of cultures grown with either Cbi or a 202 cobamide at nanomolar concentrations (Fig. 5, 6A ) suggested that C. difficile takes up Cbi and 203 cobamides via an active transporter. We identified a candidate cobalamin uptake operon 204 (btuFCD) downstream of a sequence annotated as a cobalamin riboswitch, suggesting that these 205 genes function in corrinoid import (27, 28, (65) (66) (67) (68) (69) (70) . No corrinoids could be detected in the 206 cellular fraction of the ∆btuFCD mutant grown with 10 nM Cbi or cobalamin (Fig. 6A ). In 207 contrast, ALA uptake is apparently unaffected in the ∆btuFCD mutant, as pseudocobalamin can 208 be recovered from the cellular fraction when ALA is provided (Fig. 6A ). Furthermore, the 209 ∆btuFCD mutant grew poorly in methionine-free medium even when Cbi or cobalamin was 210 added at concentrations 10 3 to 10 4 -fold higher than required for growth of the parental strain 211 (Fig. 6B ). The ability of methionine or ALA to support growth remained unaffected by the 212 ∆btuFCD mutation (Fig. 6B ). Interestingly, genomic analysis identified strains of C. difficile that 213 contain a tlpB transposon insertion in btuC, likely rendering the BtuFCD transporter 214 nonfunctional (Supplemental Fig. 3 ) (71). Of the genomes analyzed, the tlpB insertion in this 215 locus appears to be restricted to strains in the PCR-ribotype 027 (RT027) clade, including the 216 hypervirulent strain R20291, based on a multi-locus sequence typing (MLST) tree of C. difficile 217 strains (Supplemental Fig. 3, red labels) . This observation suggests that unlike strain 630 ∆erm 218 examined in this study, members of the RT027 clade may be unable to take up cobamides and 219
Cbi efficiently. The potential of C. difficile to cause disease is closely linked to its ability to fill 224 ecological niches made available by gut microbiota dysbiosis (13), using a suite of metabolic 225 pathways to make use of newly available nutrient sources. C. difficile has an unusually high 226 number of cobamide-dependent metabolisms encoded in its genome (25), but their functions 227 have been underexplored. Here, we show that C. difficile is able to use many cobamides and 228 cobamide precursors in two of its seven cobamide-dependent pathways. The promiscuous use of 229 cobamides and the ability to bypass these cobamide-dependent metabolisms highlights the 230 metabolic flexibility of C. difficile. 231
The cobalamin-dependent methionine synthase, MetH, is the most abundant cobamide-232 dependent enzyme in bacterial genomes (25) and is found in numerous organisms in all three 233 domains of life, including humans (24). Compared to the majority of other MetH homologs that 234 have been studied, our results indicate that the C. difficile MetH homolog is unusually 235 promiscuous in its cobamide selectivity. For example, several eukaryotic algae grew robustly 236 under MetH-dependent conditions with cobalamin, but did not grow with pseudocobalamin at 237 the same concentrations (33). The human gut commensal bacterium Bacteroides 238 thetaiotaomicron could use benzimidazolyl and purinyl cobamides for MetH-dependent growth, 239 but could not use phenolyl cobamides (28). An example of MetH selectivity in vitro was in 240
Spirulina platensis, where the purified enzyme bound its native cobamide, pseudocobalamin, 241 with a higher affinity than cobalamin (72). An exception to this observed selectivity is another 242 gut pathogen, Salmonella enterica, which can use its native cobamide, pseudocobalamin, in 243 addition to cobalamin, [Phe]Cba, and [Cre]Cba for MetH-dependent growth, although other 244 cobamides were not tested (48, 49). The versatility of C. difficile's cobamide use is notable given 245 the diversity of cobamides that have been detected in the gut (38). 246
In contrast to MetH, our growth experiments indicate that the selectivity of C. difficile's 247
NrdJ is more similar to that of other organisms that rely on NrdJ for growth. For example, showed that C. difficile 630 ∆erm reached maximum growth yield with as little as 1 nM 266 cobamide or Cbi (Fig 3, 4) . Based on the absence of corrinoids in the cellular fraction of a 630 267 ∆erm ∆pyrE ∆btuFCD strain (Fig. 6 ), we infer that strains with an insertion in btuC 268 (Supplemental Fig. 3 ), including the hypervirulent R20291 and CD196 strains (71), would 269 require cobamides or Cbi at extracellular concentrations higher than 100 µM if relying on 270 cobamide-dependent enzymes. This suggests that these strains may not be able to use the 271 cobamides or Cbi present in the gut. 272
Our results show that not only is C. difficile able to use multiple cobamides to support its 273 metabolism, but it can also use the early precursor ALA to produce pseudocobalamin. The ability 274 to use ALA to produce a cobamide, and thus not strictly rely on cobamide or Cbi uptake, could 275 be important to strains with a transposon insertion in the btuC gene (70, 74). ALA concentrations 276 in the human gut have not been reported. However, we speculate that, similar to cobamides and 277
Cbi, ALA and possibly other early cobamide precursors could be provided by other members of 278 the microbiota. Alternatively, ALA could be provided by the host either through the diet or via 279 biosynthesis of heme, which also uses ALA as a precursor. Other commensal gut microbiota 280 have been reported to be able to salvage ALA (25), suggesting that ALA could be available in 281 the gut. 282 C. difficile is also able to incorporate non-native lower ligands to form benzimidazolyl 283 cobamides (guided biosynthesis). Free benzimidazole bases have been found in animal 284 gastrointestinal tracts such as rumen fluid and termite guts (75), but benzimidazole levels in the 285 human gut have not been measured. The cobamides used by C. difficile could therefore also vary 286 with the presence of different benzimidazole-producing organisms in the microbiota. Our results 287
show that pseudocobalamin and most benzimidazolyl cobamides support growth of C. difficile 288 equally for the two metabolisms we investigated in this study, but the cobamide preferences of 289 the other five cobamide-dependent metabolisms have not been investigated. 290
We have identified cobamides and precursors that C. difficile can use in vitro, but which 291 cobamides or cobamide precursors it predominantly uses in the gut remains to be discovered. 292
Evidence from transcriptomics is ambiguous with respect to expression of genes encoding 293 cobamide-dependent enzymes or cobamide biosynthesis during infection, likely due to 294 differences in study design (15, 43, 76-78). Since both diet and the microbiota can contribute to 295 the cobamide profile in the gut (38, 79, 80), the availability of cobamides may vary significantly 296 across infection systems and affect the expression and use of cobamide biosynthesis and 297 cobamide-dependent pathways by C. difficile. In one study, hemB, which encodes the enzyme 298 that converts ALA to the next intermediate, porphobilinogen, was among the most highly 299 expressed genes in C. difficile strain VPI 104363 in a mouse model (43), suggesting that C. C. difficile was grown in 50 ml CDDM plus 8 g/L glucose under 80% N 2 /20% CO 2 360 headspace for 16-22 hours at 37ºC prior to corrinoid extraction. Two cultures were combined for 361 each condition for a total volume of 100 ml for each extraction. Corrinoid extractions were 362 performed as described (31), except that cell pellets were autoclaved for 35 minutes and cooled 363 prior to addition of methanol and potassium cyanide. Two or more biological replicates were 364 performed for each condition. 365
High-performance liquid chromatography (HPLC) analysis was performed with an 366 Agilent Series 1200 system (Agilent Technologies, Santa Clara, CA) equipped with a diode array 367 detector with detection wavelengths set at 360 and 525 nm. For Fig. 5B and 6A samples were 368 injected onto an Agilent Zorbax SB-Aq column (5 µm, 4.6 × 150 mm) at 30°C, with 1 mL/min 369 flow rate. Compounds in the samples were separated with a gradient of 25 to 34% acidified 370 methanol in acidified water (containing 0.1% formic acid) over 11 min, followed by a 34 to 50% 371 gradient over 2 min, and 50 to 75% over 9 min. For Fig. 5A , samples were injected onto an 372 Agilent Eclipse Plus C18 column (5 µm, 9.6 × 250 mm) at 30 ºC, with 2 mL/min flow rate. 373
Compounds in the samples were separated with a gradient of 10 to 42% acidified methanol in 374 acidified water over 20 min. The amount of standards that were injected were as follows: Cbi (1) 
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(4) are shown as standards. 
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